EVLO Profile
Evelo Biosciences Inc. (EVLO) is a biotechnology company headquartered in Cambridge, Massachusetts, USA. The company is focused on developing therapies for the treatment of cancer and inflammatory diseases by modulating the immune system through the gut.
Evelo's lead product candidate is EDP1815, an investigational therapy for the treatment of psoriasis and atopic dermatitis, two common inflammatory skin diseases. EDP1815 is designed to target the gut-liver axis by modulating the activity of immune cells in the gut, which can have downstream effects on the immune system throughout the body. EDP1815 is currently being evaluated in a Phase 2b clinical trial for the treatment of psoriasis, and the company is also planning to initiate a Phase 2 clinical trial for the treatment of atopic dermatitis in 2022. Evelo is also developing other product candidates for the treatment of various cancers and inflammatory diseases, including EDP1867 for the treatment of solid tumors.
In November 2021, Evelo announced positive data from a Phase 2a clinical trial of EDP1815 in patients with mild-to-moderate psoriasis. The data showed that EDP1815 was generally well-tolerated and demonstrated encouraging signs of clinical activity, including a reduction in the severity of psoriasis and improvement in patients' quality of life. The company plans to continue the development of EDP1815 and expects to initiate additional clinical trials in the coming months.
As of September 30, 2021, Evelo had cash, cash equivalents, and marketable securities of $165.2 million. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
|
